Faron Pharmaceuticals Oy (AIM:FARN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
43.00
+0.90 (2.09%)
Mar 25, 2026, 3:46 PM GMT
Market Cap49.79M -74.1%
Revenue (ttm)n/a
Net Income-23.78M
EPS-0.21
Shares Out115.78M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume87,576
Average Volume125,553
Open43.65
Previous Close43.00
Day's Range42.33 - 44.00
52-Week Range41.00 - 270.00
Beta1.09
RSI24.72
Earnings DateMar 4, 2026

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 33
Stock Exchange London Stock Exchange AIM
Ticker Symbol FARN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2025 Earnings Call Highlights: Clinical Successes ...

Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2025 Earnings Call Highlights: Clinical Successes and Financial Challenges

21 days ago - GuruFocus

Full Year 2025 Faron Pharmaceuticals Oy Earnings Call Transcript

Full Year 2025 Faron Pharmaceuticals Oy Earnings Call Transcript

21 days ago - GuruFocus

Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data

At IUIS 2025, Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Result...

9 months ago - IBTimes